We continue to embrace opportunities that may enable the delivery of potentially transformational medicines.

  • Takeda
    Our collaboration with Takeda Pharmaceuticals aims to accelerate the discovery and development of innovative, first-in-class therapies that address central nervous system (CNS) disorders. As part of this strategic partnership, Takeda has an option to a global 50:50 co-development and co-commercialization profit share for select CNS targets.